文献速递前列腺癌

PSMA PET/CT 在高危前列腺癌分期中具成本效益:基于 proPSMA 试验的分析

Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial.
PubMed 文献 · Eur Urol · 2020-12-16

基于 proPSMA 试验的成本效益分析显示,在高危前列腺癌初始分期中,68Ga-PSMA-11 PET/CT 每次扫描费用为 1203 澳元,低于传统影像的 1412 澳元。PSMA PET/CT 在诊断准确性更高的同时成本更低,因此具有绝对优势,为将其纳入临床实践提供了有力依据。

要点

  • PSMA PET/CT 每次扫描费用 1203 澳元,低于传统影像的 1412 澳元。
  • PSMA PET/CT 准确性更高且成本更低,每额外准确检出淋巴结病变可节省 959 澳元。
  • 每额外准确检出远处转移可节省 1412 澳元,支持将 PSMA PET/CT 纳入临床实践。

核心结论

  • 在高危前列腺癌初始分期中,PSMA PET/CT 相比传统影像直接比较成本更低且准确性更高。
  • 该结果为将 PSMA PET/CT 纳入临床实践提供了有力依据。

研究设计与样本

  • 基于 proPSMA 研究的成本效益分析,纳入高危前列腺癌患者并随机分配至传统影像或 68Ga-PSMA-11 PET/CT。
  • 分析从澳大利亚社会视角开展,采用决策树分析计算每例准确诊断的成本。

主要发现

  • PSMA PET/CT 每次扫描估计费用为 1203 澳元,低于传统影像的 1412 澳元。
  • PSMA PET/CT 具有绝对优势,即准确性更好且成本更低。
  • 每额外准确检出淋巴结病变可节省 959 澳元,每额外准确检出远处转移可节省 1412 澳元。
  • 结果对每次 68Ga-PSMA-11 生产运行所扫描男性数量的变化最为敏感。

关键数值与推荐

  • proPSMA 主要结局为诊断准确性(淋巴结和远处转移)。
  • PSMA PET/CT 每次扫描费用 AUD$1203,传统影像费用 AUD$1412。
  • 每额外准确检出淋巴结病变节省 AUD$959,每额外准确检出远处转移节省 AUD$1412。

临床怎么用

  • 在高危前列腺癌初始分期中,可优先考虑采用 PSMA PET/CT 替代传统影像。
  • PSMA PET/CT 在提高诊断准确性的同时降低直接比较成本。

局限性

  • 后续研究需评估 PSMA PET/CT 指导治疗的长期成本和获益。
  • 结果对每次 68Ga-PSMA-11 生产运行所扫描男性数量的变化最为敏感。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Before integrating prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) into routine care, it is important to assess if the benefits justify the differences in resource use. OBJECTIVE: To determine the cost-effectiveness of PSMA-PET/CT when compared with conventional imaging. DESIGN, SETTING, AND PARTICIPANTS: A cost-effectiveness analysis was developed using data from the proPSMA study. proPSMA included patients with high-risk prostate cancer assigned to conventional imaging or 68Ga-PSMA-11 PET/CT with planned health economics data collected. The cost-effectiveness analysis was conducted from an Australian societal perspective. INTERVENTION: 68Ga-PSMA-11 PET/CT compared with conventional imaging (CT and bone scan). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome from proPSMA was diagnostic accuracy (nodal and distant metastases). This informed a decision tree analysis of the cost per accurate diagnosis. RESULTS AND LIMITATIONS: The estimated cost per scan for PSMA PET/CT was AUD$1203, which was less than the conventional imaging cost at AUD$1412. PSMA PET/CT was thus dominant, having both better accuracy and a lower cost. This resulted in a cost of AUD$959 saved per additional accurate detection of nodal disease, and AUD$1412 saved for additional accurate detection of distant metastases. The results were most sensitive to variations in the number of men scanned for each 68Ga-PSMA-11 production run. Subsequent research is required to assess the long-term costs and benefits of PSMA PET/CT-directed care. CONCLUSIONS: PSMA PET/CT has lower direct comparative costs and greater accuracy compared to conventional imaging for initial staging of men with high-risk prostate cancer. This provides a compelling case for adopting PSMA PET/CT into clinical practice. PATIENT SUMMARY: The proPSMA study demonstrated that prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) better detects disease that has spread beyond the prostate compared with conventional imaging. Our analysis shows that PSMA PET/CT is also less costly than conventional imaging for the detection of disease spread. This research was presented at the European Association of Nuclear Medicine Scientific Meeting in October 2020.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. de Feria Cardet RE, Hofman MS, Segard T, et al. Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial. Eur Urol. 2020. PMID: 33341285. doi:10.1016/j.eururo.2020.11.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。